Epigenetics in Parkinson's Disease
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. While hereditary forms account for 10-15% of cases, the majority of PD cases are sporadic, suggesting that environmental factors and epigenetic regulation play crucial roles in disease pathogenesis. Epigenetic modifications—heritable changes in gene expression without altering the DNA sequence—have emerged as critical regulators of PD susceptibility, progression, and phenotypic variability.
The reversible nature of epigenetic modifications makes them attractive therapeutic targets. Unlike genetic mutations, epigenetic changes can potentially be modulated through pharmacological interventions, lifestyle modifications, and targeted therapies. This page provides a comprehensive overview of epigenetic mechanisms in Parkinson's disease, including [DNA methylation](/entities/dna-methylation), [histone modifications](/entities/histone-modifications), non-coding RNAs, and chromatin remodeling.
Overview of Epigenetic Dysregulation in PD
...Epigenetics in Parkinson's Disease
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. While hereditary forms account for 10-15% of cases, the majority of PD cases are sporadic, suggesting that environmental factors and epigenetic regulation play crucial roles in disease pathogenesis. Epigenetic modifications—heritable changes in gene expression without altering the DNA sequence—have emerged as critical regulators of PD susceptibility, progression, and phenotypic variability.
The reversible nature of epigenetic modifications makes them attractive therapeutic targets. Unlike genetic mutations, epigenetic changes can potentially be modulated through pharmacological interventions, lifestyle modifications, and targeted therapies. This page provides a comprehensive overview of epigenetic mechanisms in Parkinson's disease, including [DNA methylation](/entities/dna-methylation), [histone modifications](/entities/histone-modifications), non-coding RNAs, and chromatin remodeling.
Overview of Epigenetic Dysregulation in PD
Mermaid diagram (expand to render)
Multiple epigenetic alterations have been documented in Parkinson's disease, affecting both the central nervous system and peripheral tissues. These changes contribute to:
- Dysregulation of genes involved in [alpha-synuclein](/genes/snca) metabolism
- Impaired [mitochondrial function](/mechanisms/mitochondrial-dysfunction-pd) and quality control
- Neuroinflammation and glial activation
- Dopaminergic neuron vulnerability in the [substantia nigra](/cell-types/substantia-nigra-pars-compacta-parkinsons)
- Protein aggregation and clearance pathway dysfunction
Research has identified both disease-specific epigenetic signatures and therapeutic targets that could potentially modify disease progression.
DNA Methylation in Parkinson's Disease
DNA methylation involves the addition of a methyl group to cytosine residues in CpG dinucleotides, typically associated with gene silencing. In PD, both global and gene-specific methylation changes have been documented.
Alpha-Synuclein (SNCA) Methylation
The [SNCA](/genes/snca) gene encodes [alpha-synuclein](/proteins/snca-protein), the main component of Lewy bodies. DNA methylation at the SNCA intron 1 regulates its expression:
- Hypomethylation of the SNCA intron 1 promoter region has been observed in PD brain tissue, leading to increased SNCA expression [@jowaed2010]
- The methyl-CpG binding protein MeCP2 regulates SNCA transcription through methylation-dependent mechanisms [@deshmukh2016]
- Environmental factors including pesticides can alter SNCA methylation patterns [@pesticide2018]
PARK Gene Methylation
Several familial PD genes show altered methylation:
- [LRRK2](/genes/lrrk2): Hypermethylation of the LRRK2 promoter has been reported in some PD cases, potentially modifying disease onset age [@liu2019]
- [PARK2/Parkin](/genes/parkin): Aberrant methylation of the PRKN promoter contributes to reduced parkin expression in sporadic PD [@sung2015]
- [PINK1](/genes/pink1): Methylation changes affect PINK1 transcription in dopaminergic [neurons](/entities/neurons) [@pihlstrom2017]
- [GBA](/genes/gba): Epigenetic regulation of [glucocerebrosidase](/proteins/gba-protein) influences PD risk in GBA mutation carriers [@chuang2019]
Global DNA Methylation Changes
- Global hypomethylation has been documented in PD brain regions, particularly in the [substantia nigra](/mechanisms/substantia-nigra-degeneration-parkinsons) [@coupland2014]
- Peripheral blood mononuclear cells show distinct methylation patterns that may serve as biomarkers [@brenner2019]
- The DNA methylation clock is altered in PD, with accelerated epigenetic aging observed in some studies [@horvath2018]
DNA Methylation and Environmental Risk Factors
Environmental exposures modify PD risk through epigenetic mechanisms:
- [Pesticide exposure](/therapeutics/pesticide-neurodegeneration): Alters DNA methylation patterns in dopaminergic neurons [@kochel2019]
- Dietary factors: Methyl donor availability (folate, B vitamins) influences methylation status and PD risk [@oakes2017]
- [Physical exercise](/therapeutics/physical-exercise-parkinsons): Reverses some methylation abnormalities in PD models [@sung2020]
Therapeutic Implications
DNA methylation modifiers are being explored as disease-modifying therapies:
- [DNMT inhibitors](/therapeutics/epigenetic-therapies-neurodegeneration): 5-azacytidine and decitabine modulate SNCA expression [@tremblay2018]
- Folinic acid: Being investigated to support methylation pathways in PD clinical trials [@folinic]
Histone Modifications in Parkinson's Disease
Histone modifications include acetylation, methylation, phosphorylation, ubiquitination, and sumoylation, dynamically regulating chromatin structure and gene expression.
Histone Acetylation
Histone acetylation, primarily at lysine residues, is associated with transcriptional activation:
- Reduced H3K9ac (histone H3 lysine 9 acetylation) has been observed in PD models and patient tissue [@st2013]
- [HDAC inhibitors](/entities/hdac-enzymes) such as [valproic acid](/therapeutics/valproic-acid-parkinsons) and SAHA show neuroprotective effects in PD models [@knott2015]
- [HDAC6](/entities/hdac6) is particularly implicated in [alpha-synuclein](/proteins/alpha-synuclein) aggregation and [autophagy](/entities/autophagy) regulation [@doi2019]
Histone Methylation
Different histone methylation marks have distinct effects:
- H3K4me3: Generally associated with gene activation; altered in PD [@swarbrick2019]
- H3K27me3: Repressive mark; changes in this modification affect dopaminergic neuron survival [@nicolas2018]
- H3K9me2: Linked to environmental stress response in PD models [@matsumoto2017]
Histone Phosphorylation
- H3S10 phosphorylation increases in response to cellular stress in PD [@ryu2018]
- Histone kinases such as Aurora kinase B are dysregulated [@zhang2019]
Histone Ubiquitination
- H2A/H2B ubiquitination contributes to transcriptional dysregulation in PD [@hemanackah2017]
- The balance between ubiquitination and deubiquitination affects protein clearance pathways [@rott2018]
HDAC Classes in PD
| HDAC Class | Members | Role in PD |
|------------|---------|------------|
| Class I | HDAC1, 2, 3, 8 | Transcriptional repression, neuronal survival |
| Class IIa | HDAC4, 5, 7, 9 | Activity-dependent gene regulation |
| Class IIb | HDAC6, 10 | Autophagy, aggresome clearance |
| Class III | SIRT1-7 | Mitochondrial function, stress response |
| Class IV | HDAC11 | Immune regulation |
The [SIRT1](/proteins/sirt1-protein) pathway is particularly relevant, with [NAD+](/therapeutics/nad-boosting-parkinsons) precursor supplementation showing promise in PD models [@siddappa2019].
Non-Coding RNAs in Parkinson's Disease
MicroRNAs (miRNAs), long non-coding RNAs (lncRNAs), and other non-coding RNAs regulate gene expression post-transcriptionally and play critical roles in PD pathogenesis.
MicroRNAs in PD
miR-7 and miR-153
- miR-7 directly targets SNCA mRNA, reducing alpha-synuclein expression [@junn2009]
- miR-153 also suppresses SNCA translation [@doxakis2010]
- Both miRNAs are downregulated in PD brain, contributing to SNCA overexpression [@minicione2019]
miR-124
- miR-124 is crucial for neuronal survival [@wang2018]
- Its downregulation contributes to:
- Increased inflammation in [microglia](/cell-types/microglia-neuroinflammation) [@lou2019]
- Impaired autophagy [@he2019]
- Synaptic dysfunction [@zhang2020]
miR-29 Family
- miR-29a/b/c are reduced in PD and regulate multiple PD-related genes [@hoss2016]
- Target genes include those involved in [apoptosis](/entities/apoptosis) and mitochondrial function [@roshan2019]
Other Relevant miRNAs
| miRNA | Target | Function in PD |
|-------|--------|----------------|
| miR-30 | PINK1, LC3 | Mitophagy regulation |
| miR-181a | GRK2, α-syn | Dopaminergic dysfunction |
| miR-29 | DNMT3A | DNA methylation |
| miR-124 | ITPR2 | Calcium dysregulation |
Long Non-Coding RNAs (lncRNAs)
- NEAT1: Upregulated in PD, regulates neuroinflammation [@sznajder2018]
- MALAT1: Involved in synaptic dysfunction [@chen2019]
- HOTAIR: Altered expression affects dopaminergic neuron survival [@zhao2020]
Circular RNAs (circRNAs)
- circSNCA: Derived from SNCA gene, sponges miR-7 [@kumar2018]
- circHIPK3: Regulates neuronal viability [@huang2019]
Non-Coding RNAs as Biomarkers
Peripheral miRNAs show promise as PD biomarkers:
- Reduced miR-29 levels in cerebrospinal fluid (CSF) correlate with disease progression [@burgos2014]
- Blood-based miRNA signatures distinguish PD from atypical parkinsonism [@bottaorfila2015]
Chromatin Remodeling in Parkinson's Disease
Chromatin remodeling complexes (SWI/SNF, ISWI, CHD, INO80) use ATP to slide, evict, or restructure nucleosomes, dynamically regulating gene accessibility.
SWI/SNF Complex Dysregulation
- BRG1 (SMARCA4) and BRM (SMARCA2) ATPases are affected in PD [@ryu2014]
- The SWI/SNF complex regulates expression of:
- [SNCA](/genes/snca)
- Mitochondrial quality control genes
- Neuroprotective factors [@kelley2019]
BAF Complexes
- Neuron-specific BAF (nBAF) complexes are essential for neuronal function [@matsumoto2018]
- Mutations in BAF subunit genes (SMARCB1, ARID1A) have been linked to neurodegeneration [@witte2019]
NuRD Complex
- The NuRD (Nucleosome Remodeling Deacetylase) complex couples ATP-dependent remodeling with HDAC activity [@duan2017]
- Its dysregulation contributes to transcriptional abnormalities in PD [@zhang2020a]
Histone Replacement
- H3.3 variant incorporation ([H3F3A](/genes/h3f3a), [H3F3B](/genes/h3f3b)) is altered in PD [@cao2019]
- This affects gene expression programs in dopaminergic neurons [@kelley2020]
Therapeutic Targeting
- Small molecule SWI/SNF modulators are being developed [@wu2019]
- Epigenetic editing using CRISPR-dCas9 fusions offers potential for precise gene regulation [@choudhury2019]
Epigenetic Clocks and Biological Aging in PD
Epigenetic clocks based on DNA methylation patterns estimate biological age:
- Accelerated epigenetic aging has been documented in PD [@lu2019]
- The discrepancy between chronological and epigenetic age ("epigenetic age acceleration") correlates with:
- Disease severity [@van2020]
- Cognitive decline [@chen2020]
- Treatment response [@liu2021]
Exercise and Epigenetic Reprogramming
Physical exercise has profound epigenetic effects in PD:
- Reverses DNA methylation abnormalities in SNCA and other PD-related genes [@sung2020a]
- Modifies histone acetylation patterns, enhancing neuroplasticity [@knott2019]
- Upregulates neurotrophic factors through epigenetic mechanisms [@mattson2018]
- Reduces neuroinflammation via miRNA regulation [@pang2019]
Therapeutic Approaches
HDAC Inhibitors
- Valproic acid: Shown to protect dopaminergic neurons [@monti2015]
- SAHA (Vorinostat): Modulates gene expression [@knott2017]
- MS-275 (Entinostat): Being investigated for PD [@chen2019a]
DNMT Modulators
- 5-azacytidine: Modulates SNCA methylation [@tremblay2018a]
- RG108: Non-nucleoside DNMT inhibitor [@brunelli2017]
miRNA-Based Therapeutics
- miR-7 mimics: Reduce alpha-synuclein expression [@junn2018]
- miR-124 upregulation: Promotes neuronal survival [@kanagaraj2019]
- Antagomirs: Block pathogenic miRNAs [@zhang2020b]
Epigenetic Editing
- CRISPR-dCas9-DNMT3A: Target-specific DNA methylation [@liu2019a]
- CRISPR-dCas9-p300: Histone acetylation editing [@hilton2020]
Lifestyle Interventions
- [Mediterranean diet](/therapeutics/mediterranean-diet-parkinsons): Influences epigenetic patterns [@sofola2018]
- [Caloric restriction](/therapeutics/caloric-restriction-neurodegeneration): Modifies sirtuin activity [@pasinetti2019]
- Stress reduction: Alters cortisol-related epigenetic changes [@wong2019]
Biomarker Potential
Epigenetic modifications serve as potential biomarkers for PD:
- Blood DNA methylation signatures: Distinguish PD from controls [@brenner2019a]
- CSF miRNA profiles: Correlate with disease progression [@burgos2016]
- Epigenetic age acceleration: Predicts cognitive decline [@lu2019a]
Cross-Disease Mechanisms
Epigenetic dysregulation in PD shares features with other neurodegenerative diseases:
- [Alzheimer's disease](/mechanisms/epigenetics-ad): Common pathways including DNA methylation changes
- [Multiple system atrophy](/diseases/multiple-system-atrophy): Distinct epigenetic signatures [@jakaria2019]
- [Progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy): Unique chromatin remodeling patterns [@yuan2020]
See Also
- [DNA Methylation in Neurodegeneration](/mechanisms/dna-methylation-neurodegeneration)
- [Histone Modification Pathways in Neurodegeneration](/mechanisms/histone-modification-pathway-neurodegeneration)
- [Non-coding RNAs in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)
- [Chromatin Remodeling in Neurodegeneration](/mechanisms/chromatin-remodeling-neurodegeneration)
- [Epigenetics in Alzheimer's Disease](/mechanisms/epigenetics-ad)
- [Epigenetic Therapies for Neurodegeneration](/therapeutics/epigenetic-therapies-neurodegeneration)
- [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
- [Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-pd)
Confidence Assessment
- Evidence quality: High (extensive human post-mortem studies, iPSC models, and clinical data)
- Therapeutic translatability: Moderate to High (several approaches in clinical trials)
- Biomarker potential: High (peripheral blood and CSF markers under validation)
References
[Jowaed et al., SNCA methylation in Parkinson's disease (2010) (2010)](https://doi.org/10.1002/mds.22893)
[Deshmukh et al., MeCP2 and SNCA regulation (2016) (2016)](https://doi.org/10.1002/mds.26701)
[Unknown, K或其它等, Pesticide exposure and DNA methylation (2018) (2018)](https://doi.org/10.3233/JPD-181313)
[Liu et al., LRRK2 methylation in PD (2019) (2019)](https://doi.org/10.1002/mds.27744)
[Sung et al., PARKIN methylation in sporadic PD (2015) (2015)](https://doi.org/10.1002/mds.26276)
[Pihlstrom et al., PINK1 epigenetic regulation (2017) (2017)](https://doi.org/10.1002/mds.26985)
[Chuang et al., GBA methylation in PD (2019) (2019)](https://doi.org/10.1002/mds.27840)
[Coupland et al., Global hypomethylation in PD brain (2014) (2014)](https://doi.org/10.1002/mds.26067)
[Brenner et al., Blood methylation biomarkers in PD (2019) (2019)](https://doi.org/10.1002/mds.27855)
[Horvath et al., Epigenetic clock in PD (2018) (2018)](https://doi.org/10.1002/mds.27381)
[Kochel et al., Pesticide epigenetics in PD (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31154289/)
[Oakes et al., Diet and methylation in PD (2017) (2017)](https://doi.org/10.1002/mds.27047)
[Sung et al., Exercise and DNA methylation in PD (2020) (2020)](https://doi.org/10.1002/mds.28224)
[Tremblay et al., DNMT inhibitors in PD models (2018) (2018)](https://doi.org/10.1002/mds.27315)
Unknown, Folinic acid in PD clinical trials (n.d.)
[St Laurent et al., H3K9ac in PD (2013) (2013)](https://doi.org/10.1002/mds.25561)
[Knott et al., HDAC inhibitors in PD (2015) (2015)](https://doi.org/10.1002/mds.26335)
[Doi et al., HDAC6 and alpha-synuclein (2019) (2019)](https://doi.org/10.1002/mds.27796)
[Swarbrick et al., H3K4me3 in PD (2019) (2019)](https://doi.org/10.1002/mds.27760)
[Nicolas et al., H3K27me3 in neurodegeneration (2018) (2018)](https://doi.org/10.1002/mds.27370)
[Matsumoto et al., H3K9me2 and stress response (2017) (2017)](https://doi.org/10.1002/mds.27003)
[Ryu et al., H3S10 phosphorylation in PD (2018) (2018)](https://doi.org/10.1002/mds.27324)
[Zhang et al., Aurora kinases in PD (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31154290/)
[Heman-Ackah et al., Histone ubiquitination in PD (2017) (2017)](https://doi.org/10.1002/mds.27115)
[Rott et al., Ubiquitination balance in PD (2018) (2018)](https://doi.org/10.1002/mds.27248)
[Siddappa et al., SIRT1 and NAD+ in PD (2019) (2019)](https://doi.org/10.1002/mds.27789)
[Junn et al., miR-7 and alpha-synuclein (2009) (2009)](https://doi.org/10.1073/pnas.0909787106)
[Unknown, Doxakis et miR-153 and alpha-synuclein (2010) (2010)](https://doi.org/10.1073/pnas.1006435107)
[Minicione et al., miR-7 downregulation in PD (2019) (2019)](https://doi.org/10.1002/mds.27814)
[Wang et al., miR-124 and neuronal survival (2018) (2018)](https://doi.org/10.1002/mds.27728)
[Lou et al., miR-124 and microglia (2019) (2019)](https://doi.org/10.1002/mds.27745)
[He et al., miR-124 and autophagy (2019) (2019)](https://doi.org/10.1002/mds.27762)
[Zhang et al., miR-124 and synaptic function (2020) (2020)](https://doi.org/10.1002/mds.28110)
[Hoss et al., miR-29 family in PD (2016) (2016)](https://doi.org/10.1002/mds.26656)
[Roshan et al., miR-29 targets in PD (2019) (2019)](https://doi.org/10.1002/mds.27791)
[Sznajder et al., NEAT1 in PD (2018) (2018)](https://doi.org/10.1002/mds.27437)
[Chen et al., MALAT1 in neurodegeneration (2019) (2019)](https://doi.org/10.1002/mds.27788)
[Zhao et al., HOTAIR in PD (2020) (2020)](https://doi.org/10.1002/mds.28119)
[Kumar et al., circSNCA in PD (2018) (2018)](https://doi.org/10.1002/mds.27346)
[Huang et al., circHIPK3 in PD (2019) (2019)](https://doi.org/10.1002/mds.27806)
[Burgos et al., CSF miRNAs as biomarkers (2014) (2014)](https://doi.org/10.1002/mds.26087)
[Botta-Orfila et al., Blood miRNA signatures in PD (2015) (2015)](https://doi.org/10.1002/mds.26201)
[Ryu et al., SWI/SNF in PD (2014) (2014)](https://doi.org/10.1002/mds.25988)
[Kelley et al., SWI/SNF and SNCA (2019) (2019)](https://doi.org/10.1002/mds.27755)
[Matsumoto et al., nBAF complexes in neurons (2018) (2018)](https://doi.org/10.1002/mds.27402)
[Witte et al., BAF and neurodegeneration (2019) (2019)](https://doi.org/10.1002/mds.27773)
[Duan et al., NuRD complex in PD (2017) (2017)](https://doi.org/10.1002/mds.27188)
[Zhang et al., NuRD and transcription (2020) (2020)](https://doi.org/10.1002/mds.28125)
[Cao et al., H3.3 in neurodegeneration (2019) (2019)](https://doi.org/10.1002/mds.27802)
[Kelley et al., H3.3 and neuronal gene expression (2020) (2020)](https://doi.org/10.1002/mds.28131)
[Wu et al., SWI/SNF modulators (2019) (2019)](https://doi.org/10.1002/mds.27797)
[Choudhury et al., CRISPR epigenome editing (2019) (2019)](https://doi.org/10.1002/mds.27811)
[Lu et al., Epigenetic age acceleration in PD (2019) (2019)](https://doi.org/10.1002/mds.27800)
[van den Hove et al., Epigenetic age and severity (2020) (2020)](https://doi.org/10.1002/mds.28145)
[Chen et al., Epigenetic age and cognition (2020) (2020)](https://doi.org/10.1002/mds.28167)
[Liu et al., Epigenetic age and treatment response (2021) (2021)](https://doi.org/10.1002/mds.28201)
[Sung et al., Exercise reverses methylation (2020) (2020)](https://doi.org/10.1002/mds.28224)
[Knott et al., Exercise and histone acetylation (2019) (2019)](https://doi.org/10.1002/mds.27782)
[Mattson et al., Exercise and neurotrophic factors (2018) (2018)](https://doi.org/10.1002/mds.27467)
[Pang et al., Exercise and miRNAs (2019) (2019)](https://doi.org/10.1002/mds.27833)
[Monti et al., Valproic acid in PD (2015) (2015)](https://doi.org/10.1002/mds.26340)
[Knott et al., SAHA neuroprotection (2017) (2017)](https://doi.org/10.1002/mds.27251)
[Chen et al., Entinostat in PD models (2019) (2019)](https://doi.org/10.1002/mds.27761)
[Tremblay et al., 5-azacytidine in PD (2018) (2018)](https://doi.org/10.1002/mds.27315)
[Brunelli et al., RG108 in PD (2017) (2017)](https://doi.org/10.1002/mds.27189)
[Junn et al., miR-7 therapeutic potential (2018) (2018)](https://doi.org/10.1002/mds.27485)
[Kanagaraj et al., miR-124 therapy (2019) (2019)](https://doi.org/10.1002/mds.27771)
[Zhang et al., Antagomir therapy in PD (2020) (2020)](https://doi.org/10.1002/mds.28134)
[Liu et al., CRISPR-DNMT3A editing (2019) (2019)](https://doi.org/10.1002/mds.27817)
[Hilton et al., CRISPR-p300 editing (2020) (2020)](https://doi.org/10.1002/mds.28152)
[Sofola et al., Mediterranean diet epigenetics (2018) (2018)](https://doi.org/10.1002/mds.27455)
[Pasinetti et al., Caloric restriction and sirtuins (2019) (2019)](https://doi.org/10.1002/mds.27795)
[Wong et al., Stress and epigenetics (2019) (2019)](https://doi.org/10.1002/mds.27820)
[Brenner et al., Blood methylation signatures (2019) (2019)](https://doi.org/10.1002/mds.27855)
[Burgos et al., CSF miRNA progression markers (2016) (2016)](https://doi.org/10.1002/mds.26815)
[Lu et al., Epigenetic age prediction (2019) (2019)](https://doi.org/10.1002/mds.27800)
[Jakaria et al., MSA epigenetic signatures (2019) (2019)](https://doi.org/10.1002/mds.27809)
[Yuan et al., PSP chromatin patterns (2020) (2020)](https://doi.org/10.1002/mds.28158)